MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.74
+0.40
+3.87%
Closed 19:37 03/01 EST
OPEN
10.63
PREV CLOSE
10.34
HIGH
10.83
LOW
10.04
VOLUME
768.70K
TURNOVER
--
52 WEEK HIGH
25.50
52 WEEK LOW
0.7010
MARKET CAP
379.39M
P/E (TTM)
-6.6983
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cardiff Oncology (CRDF) Receives a Rating Update from a Top Analyst
SmarterAnalyst · 23h ago
Could The Cardiff Oncology, Inc. (NASDAQ:CRDF) Ownership Structure Tell Us Something Useful?
Simply Wall St. · 3d ago
BRIEF-Cardiff Oncology Reports Q4 And Full Year 2020 Results
reuters.com · 4d ago
Cardiff Oncology EPS misses by $0.05, beats on revenue
Cardiff Oncology (CRDF): Q4 GAAP EPS of -$0.19 misses by $0.05.Revenue of $0.12M (+33.3% Y/Y) beats by $0.09M.Press Release
Seekingalpha · 4d ago
Cardiff Oncology Q4 EPS $(0.19) Up From $(0.51) YoY, Sales $119.00K Up From $93.00K YoY
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.19) per share. This is a 62.75 percent increase over losses of $(0.51) per share from the same period last year. The company reported $119.00 thousand in
Benzinga · 4d ago
Cardiff Oncology 4Q Loss/Shr 19c >CRDF
Cardiff Oncology 4Q Loss/Shr 19c >CRDF
Dow Jones · 4d ago
Cardiff Oncology 4Q Rev $119,000 >CRDF
Cardiff Oncology 4Q Rev $119,000 >CRDF
Dow Jones · 4d ago
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
SAN DIEGO, Feb. 25, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...
PR Newswire - PRF · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRDF. Analyze the recent business situations of Cardiff Oncology Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRDF stock price target is 26.25 with a high estimate of 30.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 27.15M
% Owned: 76.85%
Shares Outstanding: 35.32M
TypeInstitutionsShares
Increased
17
4.36M
New
55
5.30M
Decreased
20
1.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.13%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Director
Rodney Markin
Chief Executive Officer/Director
Mark Erlander
Director
Thomas Adams
Independent Director
James Armitage
Independent Director
Paul Billings
Independent Director
John Brancaccio
Independent Director
Gary Jacob
Independent Director
Gary Pace
Independent Director
Lale White
  • Dividends
  • Splits
  • Insider Activity
No Data
About CRDF
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.